AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

AtriCure, Inc.

2025-FY EPS reported -$0.24 revenue$534,528,000

Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
FY 2025 revenue $534.5M (+14.9% YoY); net loss $11.4M ($0.24 loss per share) improved from $0.95 loss per share in 2024.
FY 2025 adjusted EBITDA $61.8M (+98% vs $31.1M in 2024); Q4 adj. EBITDA $19.9M vs $12.7M.
FY 2026 guidance: revenue ~$600-610M (12-14% growth); adj. EBITDA $80-82M; positive net income; adj. EPS $0.09-0.15.
U.S. revenue $435.4M (+13.7%); international $99.2M (+20.2%); growth driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.